UNSPSC 51371501: Dezocine

This classification denotes an opioid receptor agonist and opioid with the molecular formula C16H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VHX8K5SV4X, chemically known as 5,11-methanobenzocyclodecen-3-ol, 13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-, (5alpha,11alpha,13s*)-, (-)- but generally known as dezocine, which bears US NIH Compound Identifier 40841. European Medicines Agency schedules Dezocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07059MIG.

UNSPSC 51371501 Dezocine (Commodity) covers pharmaceutical products purchased by state and local government health and human services agencies, though recent solicitations under this code reflect a broader pharmaceutical procurement landscape including naloxone, generic multi-source drugs, and over-the-counter products rather than dezocine specifically. State and local buyers in this space include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work involves sourcing pharmaceuticals for community health initiatives, pharmacy benefit programs, and institutional distribution networks, with vendors required to meet FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and substantial insurance requirements including commercial general liability and network security coverage.

Geographic activity concentrates in Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving multiple states including Oregon. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment capabilities; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with evaluation weighted 75 percent on price competitiveness, contract term through June 30, 2028, and performance penalties ranging from $200 to $1,500 per violation.